Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21162423 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TSHR | |
| SCHEMBL348208 | 0.73 | TSHR (0.40) | LMNAALDH1A1TSHR | |
| SCHEMBL17734223 | 0.73 | ALDH1A1 (0.32) | ALDH1A1TSHR | |
| SCHEMBL116714 | 0.72 | — | — | |
| SCHEMBL6986580 | 0.72 | — | — | |
| SCHEMBL24086838 | 0.69 | TDP1 (0.36) | ALDH1A1 | |
| SCHEMBL21162424 | 0.69 | — | — | |
| Pivalate SCHEMBL28876895 | 0.69 | TSHR (0.40) | ALDH1A1TSHR | |
| SCHEMBL17953040 | 0.67 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL3077314 | 0.67 | ALDH1A1 (0.35) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20160244399-A9 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2016-08-25 | — | — | US | disclosed |
| US-9399701-B2 | Polymer compositions and methods | NOVOMER, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9139672-B2 | Polymerizable compound, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20140346399-A1 | POLYMERIZABLE COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20130172482-A1 | POLYMER COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130027654-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2013-01-31 | — | — | US | disclosed |
| EP-0664286-B1 | Tetralin nitriles, their use as ingredients for perfumes and oxime intermediates for their preparation | FIRMENICH & CIE (CH) | 1998-04-22 | — | — | EP | disclosed |
| US-5521151-A | Tetralinic nitriles, their use as perfuming ingredients and aldehyde intermediates for their preparation | FIRMENICH S.A. (CH) | 1996-05-28 | — | — | US | disclosed |
| EP-0664286-A1 | Tetralin nitriles, their use as ingredients for perfumes and oxime intermediates for their preparation | FIRMENICH SA (CH) | 1995-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244399-A9 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | VCL, LASP1, LIMA1 | LMNA 895/4885ALDH1A1 4226/4885TSHR 4553/4885 |
| US-20130027654-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | VCL, LASP1, LIMA1 | LMNA 895/4885ALDH1A1 4226/4885TSHR 4553/4885 |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | LMNA 3514/4885ALDH1A1 3193/4885TSHR 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.